• Explore /
  • Poster
  • / Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.

Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.

Abstract Poster

Authors

null

Minke W. Lucas

The Netherlands Cancer Institute, Amsterdam, Netherlands

Minke W. Lucas , Reetta Arokoski , Alexander M. Menzies , Saskia Pulleman , Robyn P.M. Saw , Winan J. van Houdt , Mark B Faries , Caroline Robert , Paolo Antonio Ascierto , Celeste Lebbe , Matteo S. Carlino , Ellen Kapiteijn , Karijn Suijkerbuijk , Piotr Rutkowski , Shahneen Sandhu , Astrid Aplonia Maria Van Der Veldt , Georgina V. Long , Christian U. Blank , Lonneke van de Poll-Franse , Judith Lijnsvelt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT04949113

Citation

J Clin Oncol 42, 2024 (suppl 17; abstr LBA9584)

DOI

10.1200/JCO.2024.42.17_suppl.LBA9584

Abstract #

LBA9584

Poster Bd #

368

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Annual Meeting

Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.

Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.

First Author: Paul Lorigan

First Author: Minke W. Lucas

First Author: Milton Jose De Barros E Silva

First Author: Anna Maloney